# Hyperfine, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Hyperfine, Inc.).

## Overview

Hyperfine, Inc. designs and commercializes the Swoop® portable MRI system, a low-field brain imaging platform used in hospitals and other care settings. The company combines hardware, software, and AI/cloud-enabled features to expand access to brain imaging beyond traditional MRI suites and into more decentralized clinical workflows.

## Products & services

• Swoop® portable MRI system
• Next-generation Swoop® system with Optive AI software
• Brain imaging clinical decision support platform
• Device sales to hospitals and clinics
• Service and support for installed systems

- **MRI device sales** (71%) — Sales of the Swoop® system and related hardware to healthcare providers.
- **Service revenue** (29%) — Support, maintenance, and related services for installed systems.

- Swoop® portable MRI system
- Next-generation Swoop® system with Optive AI software
- Brain imaging clinical decision support platform
- Device sales to hospitals and clinics
- Service and support for installed systems

## Customers

Hyperfine sells primarily to hospitals and hospital systems that want brain imaging at the point of care, especially in critical care and emergency settings. It is also expanding into hospital-based neurology clinics and outpatient neurology offices, where portability and lower infrastructure requirements can broaden MRI access. International customers include healthcare providers in Canada, Europe, Australia, and New Zealand as the company expands regulatory approvals and commercialization.

- **U.S. hospitals and hospital systems** (primary) — Buy Swoop® systems for inpatient and critical-care brain imaging and to improve access without a traditional MRI suite.
- **Emergency departments** (secondary) — Use the portable system for rapid neuro assessment and triage when speed and bedside access matter.
- **Hospital-based neurology clinics** (secondary) — Buy the system to support routine neurological imaging in a more flexible outpatient-like setting.
- **Neurology offices** (emerging) — Adopt the platform for outside-the-hospital imaging use cases as commercialization broadens.
- **International healthcare providers** (emerging) — Purchase the system in markets where regulatory approvals now allow commercialization and MRI penetration is lower.

- U.S. hospitals and hospital systems buying point-of-care brain imaging
- Critical care units needing rapid bedside MRI access
- Emergency departments seeking faster neuro imaging workflows
- Neurology clinics and offices expanding outpatient imaging access
- International healthcare providers in approved markets

## Geography

Revenue is generated in the United States and in selected international markets. The company has begun commercialization in Canada, parts of Europe, Australia, and New Zealand, and recent CE/UKCA approvals support broader European expansion. Geography matters because market access depends on local regulatory clearances, and international expansion is tied to regions with unmet MRI demand and lower installed imaging capacity.

- United States is the core commercial market and initial launch base
- Canada is an early international market with Health Canada authorization
- Europe is expanding after CE Mark and UKCA approvals
- Australia and New Zealand are approved commercialization markets
- International growth targets regions with low MRI penetration

## Strategy

Hyperfine is focused on expanding adoption of the Swoop® system through direct U.S. sales coverage, broader clinical use cases, and international market entry. The company is also investing in AI and cloud capabilities to make the platform more valuable as a brain imaging and clinical decision support tool, which could strengthen differentiation and support future profitability.

- **Broaden U.S. clinical use cases** (short-term) — Expands the addressable market beyond initial critical-care customers and increases system utilization.
- **Expand international commercialization** (medium-term) — Regulatory approvals in Canada, Europe, Australia, and New Zealand create new growth channels.
- **Advance AI and cloud-enabled product capabilities** (medium-term) — Software enhancements can improve product differentiation and support a higher-value clinical workflow offering.

- Expand U.S. adoption through direct sales and field support
- Broaden use beyond critical care into EDs and neurology clinics
- Launch and commercialize the next-generation Optive AI system
- Scale international sales in approved markets
- Develop new imaging applications and cloud-enabled decision support

## Risks

Hyperfine remains exposed to commercialization risk because adoption depends on convincing hospitals to change imaging workflows and purchase a new category of device. The company also faces financing and listing risk, as it has disclosed Nasdaq bid-price noncompliance and ongoing dependence on capital access to fund development and expansion. As a medical device company, it also faces regulatory, reimbursement, product performance, and international execution risks.

- **Nasdaq delisting risk** [high] — The company received notice that its Class A common stock fell below the minimum bid price requirement.
- **Commercial adoption risk** [high] — Revenue depends on hospitals and clinics adopting a new portable MRI workflow and sustaining utilization.
- **Financing and liquidity risk** [high] — The company states that access to capital is not assured and may be needed to fund operations and expansion.
- **Regulatory and market-access risk** [medium] — Commercialization in each geography depends on device clearances and local approvals.

- Nasdaq bid-price noncompliance could threaten listing and liquidity
- Commercial adoption may be slower than expected in hospitals and clinics
- Capital needs may outpace available cash if growth or R&D slows
- Regulatory approvals are required for each market and product version
- International expansion adds execution and compliance complexity

## Accounting

Revenue is driven by a mix of device sales and service revenue, so the timing of system placements versus ongoing support affects quarterly results. Investors should also watch estimates and judgments around capitalization, development spending, and any future impairment or valuation issues as the company continues to invest in product innovation and market expansion.

- **Revenue recognition by product and service type** — Can create volatility in reported revenue and gross margin mix.
- **Going-concern and liquidity assessment** — Affects disclosure, investor perception, and financing assumptions.
- **Equity issuance and warrant accounting** — Impacts share count, capital structure, and potentially fair value measurements.
- **Estimates and judgments in development-stage operations** — Can materially affect reported operating results and asset valuations.

- Device and service mix affects quarterly revenue timing
- Revenue can be volatile because system sales are lumpy
- R&D spending may rise as AI and new applications are developed
- Capital raises and warrants can affect equity and dilution
- Estimates and judgments matter for going-concern and valuation

---

*Last updated: 2026-04-28T20:15:19.947296+00:00*